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Heart·reactive antibodies are commonly observed in pa·
tients with myocarditis or cardiomyopathy. Such antibodies
may be important in the pathogenesis of these disorders, yet
the specific antigens recognized have not been studied
systematically. This report characterizes circulating heart
autoantibodies from patients with myocarditis (n =17) or
idiopathic cardiomyopathy (n = 71) and from healthy
volunteers (n =15). Indirect immunofluorescence demon-
strated that high titer (2=1:20) immunoglobulin G (IgG)
antibody activity occurred in 59% of the myocarditis
samples, 20% of the cardiomyopathy samples and none of
the normal samples.
All samples were tested by Western immunoblotting for
IgG activity against a normal human heart extract. The
number of antigens recognized by each sample was eilU'
merated and the molecular weight of each antigen esti-
Circulating heart-reactive antibodies have been reported
(1-7) in patients with heart disorders including myocarditis
and cardiomyopathy. Various scenarios for the induction of
these autoantibodies have been proposed. These include
cross-reactive antigens shared by various pathogens and
host tissues (8-12), alteration or aberrant expression of
self-antigens as a consequence of infection, inflammation or
necrosis (13-15) and idiotypic antibody reactivity with self-
antigens (16,17). Although associations between heart-
reactive antibodies and infectious heart disease or heart
trauma are well documented, heart autoantibodies are also
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mated; the prevalence of reactivity against antigens in
selected molecular weight classes was determined. There
was no difference in the mean number of heart antigens
recognized by serum from each group. For most weight
classes, prevalence either did not differ significantly among
the various groups or subgroups or was greatest among
samples from healthy volunteers. Prevalence of reactivity
with 190 to 199 kilodalton (kd) antigens was greatest (p <
0.05) among low titer serum samples trom patients with
myocarditis. High titer cardiomyopathy serum differed
from normal Serum by an increased (p < 0.05) prevalence
of antibodies to 40 to 49 and 100 to 109 kd antigens.
These reslilts suggest that western immunostaining may
ultimately contribute substantively to identifying patients
with myocarditis or cardiomyopathy.
(J Am Coll CardioI1990;16:839-46)
associated with myocarditis and cardiomyopathy of un-
known origin.
Typically, most demonstrations of heart autoantibodies
have relied on immunohistochemical procedures or cytotox-
icity assays (1.4), which yield valuable information but
provide little insight into the identity of the reactive antigen
or antigens. Serum from patients with viral myocarditis
exhibits multiple immunohistochemical staining patterns;
those sera that react with myocyte membranes can lyse
xenogenic myocytes in the presence of complement (4).
Several investigators have tested patient sera for antibodies
to specific antigens. Schultheiss et al. (5-7) found that some
patients with cardiomyopathy have antibodies to adenosine
nucleotide translocator proteins from heart mitochondria.
Recent reports (l8,19) suggest that these antibodies cross-
react with connexon or other myocyte surface molecules.
Experimentally induced antibodies to the adenosine nucleo-
tide translocator molecule cross-react with calcium channel
complex proteins of cardiac myocytes (20). Antibodies to
beta-adrenergic receptors were observed in serum from
some patients with idiopathic dilated cardiomyopathy (21).
Other patients with myocarditis or cardiomyopathy have
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antibodies to laminin (22); similar antibodies are common in
patients with chagasic myocarditis (11,12). Heart autoanti-
bodies from mice infected with coxsackievirus B3, a com-
mon cause of human viral myocarditis, react principally with
the heavy chain of cardiac myosin (23).
Although antibodies to specific antigens are found among
some subsets of patients with myocarditis or cardiomyopa-
thy, there has been no systematic study of antibody recog-
nition of molecules present in the normal heart. The demon-
stration that antibodies from patients with myocarditis or
cardiomyopathy react with normal heart tissue constituents
would support the hypothesis that autoimmune processes
may contribute to the pathogenesis of these disorders. The
purpose of this investigation was to screen serum for heart-
reactive antibodies from patients with active or borderline
myocarditis, idiopathic cardiomyopathy or no history of
heart disease. The initial screening by indirect immunofluo-
rescence provided a semiquantitative but relatively insensi-
tive method of testing for reactivity with heart tissue. The
second screening procedure, Western immunostaining, pro-
vided a more sensitive but qualitative measure of antibody
recognition of molecules in normal heart tissue. The results
suggest that the less sensitive procedure may identify pa-
tients for whom autoimmunity may be a significant factor
and that the more sensitive procedure may ultimately lead to
the identification of relevant cardiac antigens.
Methods
Study groups. Serum was collected from 88 patients with
congestive heart failure of recent onset (within 6 months)
and evidence of persistent left ventricular dysfunction de-
spite conventional medical therapy with diuretic drugs,
digoxin and, frequently, vasodilators. Each patient under-
went an initial evaluation that included medical history,
physical examination, routine hemograms and serum chem-
istry determinations and screening for pheochromocytoma,
collagen-vascular disease and thyroid function abnormali-
ties. Endomyocardial biopsy was subsequently performed
on each patient by the staff of the division of cardiology at
The Johns Hopkins Hospital: informed consent was ob-
tained at this time.
The myocarditis group included 17 patients (8 with histo-
logically defined active myocarditis consistent with the Dal-
las criteria [24] and 9 with borderline myocarditis). The
remaining 71 patients had no histologic evidence of myo-
carditis, but fulfilled clinical criteria for idiopathic dilated
cardiomyopathy; no patient with hypertrophic or restrictive
cardiomyopathy was included in the study. Serum from 15
healthy volunteers (Johns Hopkins Medical Institutions
staff) with no history of heart disease was obtained for
comparative purposes. Patients with myocarditis ranged in
age from 21 to 72 years (mean 32.2), patients with cardio-
myopathy from 7 to 68 years (mean 40.2) and healthy
volunteers from 21 to 42 years (mean 32.2). All sera were
stored at -70°C until evaluated.
Indirect immunofluorescence. An aliquot of each serum
sample was serially diluted in phosphate-buffered saline
solution (pH 7.2). Undiluted serum and each dilution were
incubated on 4 JLm frozen sections of normal rat heart for 30
min in a humid chamber. This and subsequent incubations
and washes were performed at room temperature. Tissue
sections were washed for 30 to 40 min in phosphate-buffered
saline solution. A fluorescein-conjugated goat antihuman
immunoglobulin G (lgG)-specific antibody diluted I:40 in
phosphate-buffered saline solution containing rhodamine (I:
20) was reacted with the tissue sections for 30 min in a humid
chamber. After washing, the sections were mounted and
stored in the dark at 4°C until examination by fluorescence
microscopy, usually within 24 h of preparation. For each
group of samples, appropriate control samples were used to
evaluate endogenous fluorescence and nonspecific binding of
the conjugate: a sample with proved high titer antiheart
reactivity was used as a positive control sample. If any of the
control samples were unacceptable, the assay was repeated.
Titer was recorded as the greatest dilution at which a distinct
fluorescent signal was observed.
Western immunostaining: electrophoresis and transfer to
nitrocellulose. A 10% (weight/volume) extract of human
myocardium was prepared in 1% Triton-X 100, 0.1 M
potassium chloride, 2 mM magnesium chloride, 2 mM
ethylenediaminetetraacetic acid (EDTA) and 0.5 mM dithio-
threitol at pH 7 (23): aliquots were stored in liquid nitrogen
until used. The tissue was obtained at The Johns Hopkins
Hospital from an 18 year old white male patient with
Eisenmenger syndrome who received a heart-lung transplant
at a time when he was not hemodynamically compromised.
The heart weighed 270 g and the left ventricular wall
thickness was 0.8 em. Tissue was obtained from the left
ventricular free wall far removed from the interventricular
septum. Pretransplant two-dimensional echocardiography
revealed normal left ventricular function and histologic
examination found no significant abnormalities within the
left ventricular myocardium. Specifically. there was no
evidence of myocyte necrosis, inflammation. hypertrophy or
fibrosis.
Aliquots of the heart extract were mixed with an equal
volume of sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis sample buffer, heated at 100°C for 5 min and
centrifuged (Brinkman model 5412 microcentrifuge) for 5
min at 15,000 rpm. A 120 JLl sample of the extract in sample
buffer was loaded onto a 5% to 12% linear gradient poly-
acrylamide minigel (Hoefer Scientific Instruments). Gels
were prepared in 0.1 M Tris hydrochloride. 0.1 M Bicine and
0.1 %sodium dodecyl sulfate at pH 8.6 and run in an identical
electrode buffer (23). Each gel was cast using a smooth comb
with a single reference well loaded with 7 JLl of prestained
molecular weight markers (BRL). Electrophoresis was per-
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formed at room temperature at 55 V until the tracking dye
reached the bottom of the gel (approximately 2 h).
After each electrophoretic separation, a small piece was
cut from the end of each gel and stained with Coomassie blue
(Sigma Chemical) to evaluate the efficacy of the separation.
The remainder of each gel was placed on a piece of nitrocel-
lulose (BA-85, 0.45 pm, Schleicher & SchueIII and the top
and bottom of the gel and the positions of each molecular
weight marker were indicated by perforating the membrane.
Molecules in the gel were electrotransferred to the mem-
brane at 110 rnA in 25 mM Trizma base, 0.2 M glycine, pH
8.3 buffer at 4°C over 2.5 h (23). The nitrocellulose was dried
overnight in the dark at room temperature and was subse-
quently cut into 2 to 3 mm wide strips for immunostaining.
Western immunostaining: processing of nitrocellulose.
Representative strips from each transfer were stained for
protein with the Biotin-blot protein assay (Bio-Rad Labora-
tories) to monitor transfer efficacy. The position of each
molecular weight marker on the nitrocellulose strip was
measured relative to the origin and to the bottom of each
respective gel. The acrylamide concentration at the position
of each marker was estimated by linear interpolation (25,26).
A molecular weight standard curve based on the log acryl-
amide concentration and log molecular weight of each
marker was determined for each gel. Each standard curve
was used to estimate the molecular weights for bands of
immunoreactivity on nitrocellulose strips from the corre-
sponding gel.
The immunostaining procedure was hased on that of
Alvarez et al. (23). Nitrocellulose strips were processed in a
24 trough tray (Hoefer Scientific Instruments) using 2 ml of
each solution per strip; all incubations and washes were
performed with constant shaking. Protein binding sites on
the membrane were blocked with 0.05 M Trizma base. 0.15
M sodium chloride and 0.05% Tween 20 at pH 8 (Buffer 1)
containing 5% (weight/volume) nonfat dry milk (Carnation)
(Buffer 2) for 2 h at room temperature. The strips were
incubated overnight at 4°C in serum diluted I:50 in Buffer 2
and then washed five times for 10 min each with the same
buffer, followed by one rapid rinse in Buffer 1. All subse-
quent incubations and washes were performed at room
temperature. Biotinylated goat antihuman IgG (Vector Lab-
oratories) diluted I:200 in Buffer I was incubated with the
strips for 30 min. Strips were washed three times over 10 min
with Buffer I before adding an avidin/biotinylated horserad-
ish peroxidase complex (Vector Laboratories) prepared in
Buffer I according to the manufacturer's directions. After
I h. the strips were washed three times with Buffer I and the
substrate 4-chloro-I-naphthol (Sigma Chemical) was added.
Color development was stopped after 10 to 20 min to
maximize the signal to noise ratio.
For each assay. control strips were used to test for
nonspecific hinding of the suhstrate, the avidin/biotinylated
horseradish peroxidase complex or the antihuman IgG to
constituents of the heart extract. Well characterized highly
reactive and poorly reactive sera were used as positive and
negative control samples, respectively. Bands of immuno-
reactivity were identified by colored product deposition. The
position of each band was measured relative to the top of the
strip and this information was used to calculate the apparent
molecular weight from the appropriate standard curve.
Data analysis. The number of cardiac antigens recog-
nized by each serum sample by Western immunostaining
was determined. The mean number of antigens recognized
by serum from each patient group was compared by Stu-
dent's t test. The molecular weight of each antigen was
estimated and each was assigned to a molecular weight class.
For graphics, class limits were 19 kilodaltons (kd) for anti-
gens between 10 and 190 kd and 34 kd for those between 190
and 224 kd; all antigens with molecular weights between 225
and 300 kd were placed in a single class. For chi-square
analysis of the prevalence of reactive samples from each
group, class limits were 9 kd for antigens between 10 and 199
kd and 24 kd for those between 200 and 299 kd. Where
prevalence differed significantly (p ~ 0.05) between groups,
data from the myocarditis and cardiomyopathy groups were
compared by Fisher's exact test.
Results
Indirect immunofluorescence. This procedure revealed
three distinct but not mutually exclusive staining patterns:
fibrillary (Fig. IA), sarcolemmal (Fig. IB) and diffuse cyto-
plasmic (Fig. IB). Circulating heart-reactive IgG titers
ranged from zero (that is, no detectable reactivity with
undiluted serum) to I:320. When all 103 samples were
considered. a bimodal distribution of titer values was ob-
served, with some samples having a low titer (~1: 10) and
others having a high titer (21 :20). Serum from individuals
with no history of heart disease were exclusively among the
low titer group. The high titer group included 59% of the
samples from patients with myocarditis and 20% of the
samples from patients with cardiomyopathy.
Western immunostaining. This procedure demonstrated
that heart-reactive IgG was present in nearly all of the
samples tested independent of the presence or absence of
heart disease; 6 of the 103 samples exhibited no heart
reactivity. Individual samples reacted with as many as 24
distinct heart constituents (Fig. 2). There were no significant
differences between the average number of antigens recog-
nized by serum from each of the sample groups or from the
low and high titer subgroups identified by indirect immuno-
fluorescence.
The percent of individuals within each sample group and
each suhgroup (low titer or high titer by indirect immuno-
fluorescence) exhibiting antibody activity against antigens in
each of the molecular weight classes was determined (Fig.
3). Chi-square analysis indicated that significant differences
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Figure 1. Immunofluorescence staining patterns of normal rat heart
by serum from patients with myocarditis or idiopathic cardiomyop-
athy. A, Fibrillary staining. B, Sarcolemmal (open arrows) and
diffuse cytoplasmic (closed arrow) staining. Immunofluorescence
was performed as described in the text.
in prevalence of reactivity occurred among the three groups
for antigens in the 50 to 59, 110 to 119, 130 to 139, 140 to 149,
170 to 179 and 225 to 249 kd classes (Table I). The preva-
lence of reactive serum was greatest among the normal
samples, whereas the prevalence of reactivity did not differ
between the myocarditis and cardiomyopathy groups. For
the remaining 17 molecular weight classes, the prevalence of
reactivity did not differ significantly among the three groups.
Significant differences in prevalence were found between
the normal samples and samples from patients with myo-
carditis or cardiomyopathy with low titers of heart reactivity
by indirect immunofluorescence for the 50 to 59, 130 to 139,
140 to 149, 170 to 179 and 190 to 199 kd classes (Table I). For
the latter class, prevalence was greatest among the sera from
patients with myocarditis with a low titer of heart-reactive
antibodies by indirect immunofluorescence and was signifi-
cantly (p = 0.014) greater than the prevalence among low
titer cardiomyopathy sera by Fisher's exact test. For each of
Figure 2. Representative Western immunostaining patterns by se-
rum from patients with myocarditis or idiopathic cardiomyopathy
and from volunteers with no history of heart disease. Note that the
number and positions of antigens recognized by each sample are
variable; some antigens are recognized by virtually all samples.
Assays were performed as described in the text; strips A, Band C
are the substrate, avidin/biotinylated horseradish peroxidase com-
plex and conjugate control sample, respectively. Strip 0 was
incubated with serum from a healthy volunteer; strips E, F and M
with sera from patients with cardiomyopathy; strip G with serum
from a patient with Hashimoto's thyroiditis; strips Hto Kwith sera
from patients with myocarditis; and strip L with serum from a
patient with acquired immunodeficiency syndrome and cardiomy-
opathy. Strip Nwas incubated with serum from a patient with active
myocarditis and congestive heart failure; strip 0 was incubated with
serum from the same patient taken 2 months after receiving a heart
transplant.
the other four molecular weight classes, the prevalence of
reactivity was greatest among the normal samples, whereas
the prevalence of reactivity did not differ significantly be-
tween the two patient groups. The prevalence of reactivity
against each of the other 18 molecular weight classes did not
differ significantly among the three groups.
There were significant differences in the prevalence of
reactivity by indirect immunofluorescence with 40 to 49, 50
to 59, 100 to 109, 140 to 149 and 170 to 189 kd antigens
between normal samples and samples from patients with
myocarditis or cardiomyopathy and a high titer of heart-
reactive antibodies (Table I). The prevalence of reactivity
with 40 to 49 and 100 to 109 kd antigens was greatest among
the patients with cardiomyopathy with a high titer of anti-
heart antibodies. For the 40 to 49 kd class, the prevalence of
reactivity was similar among both the myocarditis and
cardiomyopathy samples, whereas for the 100 to 109 kd class
prevalence was significantly (p = 0.033) greater among the
cardiomyopathy samples than among the myocarditis sam-
ples by Fisher's exact test. The prevalence of reactivity with
cardiac antigens in the 50 to 59, 140 to 149 and 170 to 179 kd
classes was greatest among the normal samples and did not
differ significantly between the two patient groups. There
lACC Vol. 16, No.4
October 1990:839-46
NEUMANN ET AL.
AUTOANTIBODIES IN MYOCARDITIS/CARDIOMYOPATHY
843
Table 1. Prevalence of Serum Reactivity With Heart Antigens
From Arbitrarily Defined Molecular Weight (MW) Classes
MW Class Normal Cardiomyopathy Myocarditis Chi-Square
All Patients
50-59 14/15 38/71 8117 9.12*
110-119 8/15 14/71 3117 8.10*
130-139 10/15 22/71 6117 6.79*
140-149 9/15 12/71 3117 13.24*
170-179 10/15 24/71 3/17 8.76*
225-249 3/15 0/71 2117 12.83*
Patients With a Low Titer
50-59 14/15 32/57 2/7 10.23*
130-139 10/15 13/57 1/7 11.47*
140-149 9/15 10/57 1/7 11.82*
170-179 10/15 20/57 1/7 6.97*
190-199 3/15 3/57 3/7 10.09*
Patients With a High Titer
40-49 3/15 10/14 3/10 8.59*
50-59 14/15 6/14 6/10 8.57*
100-109 4/15 8/14 1/10 6.32*
140-149 9/15 2/14 2/10 7.89*
170-179 10/15 4/14 2/10 6.80*
*p ,,; 0.05. Molecular weight is expressed in kilodaltons and reactive
antigens were assigned to classes as described in the text. Prevalence between
patient groups was tested by chi-square analysis. Patient groups were com-
pared both independently of the heart-reactive antibody titer determined by
indirect immunofluorescence and after separation into low (";1:10) and high
(2: I:20) titer subgroups. Only those molecular weight classes with significant
(p ,,; 0.05) chi-square values are presented; for the other molecular weight
classes. there were no significant differences between groups or subgroups.
age-related differences between the number of antigens
recognized by the respective sera. Among patients with
cardiomyopathy, there was a significant (p < 0.05) positive
correlation (r = 0.274, n = 71) between the indirect immu-
nofluorescence titer and the number of cardiac antigens
recognized by their serum. The number of cardiac antigens
recognized by myocarditis serum was unrelated to the indi-
rect immunofluorescence titer (r = 0.18, P = NS, n = 17).
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Figure 3. Prevalence of heart-reactive antibodies in serum from
patients with myocarditis or idiopathic cardiomyopathy and from
healthy volunteers with no history of heart disease. Prevalence is
defined as the percent of samples from each patient group that
recognizes cardiac antigens in each of the arbitrarily constructed
molecular weight classes (for example, 10 to 19 and 20 to 29 kd).
Percents are presented for groups of patients with myocarditis or
cardiomyopathy found to have a high or a low titer of heart-reactive
antibodies by indirect immunofluorescence.
were no statistical differences in the prevalence of reactivity
of sera from the three groups with any of the other classes.
There was no sinRle antigen or set ofantigens associated
with any of the sample groups. There were no gender- or
Discussion
Heart-reactive autoantibodies and patterns of antigenic
activity. This investigation presents a systematic evaluation
of heart-reactive antibodies in sera from patients with myo-
carditis or cardiomyopathy as well as from healthy individ-
uals. The most striking finding was that the indirect immu-
nofluorescence procedure identified subgroups of patients
with myocarditis (59%) or cardiomyopathy (20%) with a high
titer of heart autoantibodies. Conversely, the more sensitive
western immunostaining procedure, which is potentially able
to identify the specific antigens recognized by heart-reactive
antibodies, failed to discriminate among patient subgroups.
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Antiheart activity was not detected in 55 of 103 samples
evaluated by indirect immunofluorescence, whereas all but 6
samples exhibited immunoreactivity by Western immunos-
taining.
The nearly ubiquitous distribution of heart autoantibod-
ies and the multiplicity ofantigens recognized by these sera,
demonstrable by both indirect immunofluorescence and
western immunostaining, suggest that no single pattern of
antigen reactivity is unique to either of the patient groups
studied. However, both patient groups could be classified
into low and high titer subsets based on indirect immunoflu-
orescence titer. These subgroups generally did not differ in
their ability to recognize cardiac antigens from defined
molecular weight classes. The prevalence of reactivity with
cardiac antigens from the various molecular weight classes
was similar to or less than the prevalence observed in
samples from healthy volunteers. Only in the case of myo-
carditis serum with a low titer by indirect immunofluores-
cence was the prevalence of antibody activity against a
particular class (that is, 190 to 199 kd) greater among
myocarditis samples than among the other samples. Simi-
larly, high titer cardiomyopathy sera exhibited a greater
prevalence of reactivity against 40 to 49 and 100 to 109 kd
heart-reactive antigens. Although the specific identity of the
reactive antigens is not known, it is possible that the 190 to
199 kd class includes the heavy chain of cardiac myosin and
that the 40 to 49 kd class includes actin.
Technical considerations: the problem of antigen identifi·
cation. The results indicate that the screening procedures
used in this study to evaluate sera for heart-reactive anti-
bodies are unlikely to identify any single cardiac antigen as a
unique marker of autoimmune heart disease. The multiplic-
ity of staining patterns and titers obtained by indirect immu-
nofluorescence provides a rapid screening test but is not
amenable to identifying specific cardiac antigens. The west-
ern immunostaining procedure can potentially identify spe-
cific cardiac antigens, but its inability to distinguish among
patient groups in the present study suggests that it warrants
further development. This inability to demonstrate unique
disease-associated heart autoantibodies may be interpreted
as refuting the hypothesis that autoimmune processes may
be relevant in some cases of myocarditis leading to cardio-
myopathy. However, it is clear that technical factors such as
how the extract was prepared and the serum dilution could
influence the outcome of such a procedure. For example, it
is not known whether the heart extract used in this study
actually contained laminin (lU2), the adenosine nucleotide
translocator (6,7) or branched chain ketoacid dehydrogenase
(18) proteins and calcium channel proteins (19-21) that have
been associated with heart disease.
Four alternative approaches may help to resolve the
problem of cardiac antigen identification. First, the use of
two-dimensional gel electrophoresis and Western immuno-
staining would promote cardiac antigen separation and dis-
crimination. Second, comparative studies using a panel of
monospecific antibodies against various heart constituents
would facilitate unambiguous identification of some cardiac
autoantigens by Western immunostaining. Third, by using
other types of extracts or cellular fractions to better define
antigen populations, it may be possible to more clearly
identify antigens of interest. Such fractionations would en-
rich for certain types or classes of molecules, thus enhancing
the specificity of the serologic assays. A fourth approach
would use purified or partially purified heart constituents (for
example, contractile elements, sarcolemma or mitochondria)
or products of recombinant deoxyribonucleic acid (DNA)
technology as antigen sources.
Demonstration ofcardiac autoantibodies raises the ques-
tion of whether these antibodies are heart specific or are
cross-reactive with other types of muscle. For example,
myosin exists in multiple isoforms that are differentially
distributed not only between heart and skeletal muscle (27),
but also within the heart (28,29). In murine models of
autoimmune myocarditis, antibody activity against cardiac
myosin could be completely absorbed with cardiac myosin,
but not with skeletal muscle myosin (14,23). This suggests
that heart-reactive serum may include both heart-specific
and heart cross-reactive antibodies. Because antigenic spec-
ificity is a key concept in organ-specific immunopathogenic-
ity, future assays must consider this issue.
Induction of heart-reactive antibodies. A number of stud-
ies indicate that heart autoantibodies, often to myosin, are
associated with bacterial infections (8,10), viral infections
(1,3), surgery (30) and acute ischemic heart injury (3 IJ2). It
is unclear how the immune response to myosin is initiated
and whether the resulting antibodies are involved in ongoing
pathogenesis. In rheumatic carditis, induction of antimyosin
antibodies has been associated with antigenic mimicry be-
tween the streptococcal M-protein and myosin (9,10). Sur-
gery, ischemic injury or heart trauma may induce antimyosin
antibodies by damaging myocytes, thus making myosin
accessible to immunocompetent cells. For individuals with-
out heart infection or traumatic injury, the mechanisms
leading to the induction of heart-specific autoantibodies are
more tenuous.
Studies (14,33,34) in mice suggest that autoimmune myo-
carditis occurs in genetically susceptible strains either as a
sequela to virus infection or in response to immunization
with cardiac myosin. The risk of developing idiopathic
dilated cardiomyopathy was increased among patients ex-
hibiting certain major histocompatibility complex (MHC)
haplotypes (21,35). Similar restrictions in MHC haplotype
expression are common in other autoimmune disorders
(36-38). Those patients who are genetically at risk and who
experience heart infection or injury may develop chronic
autoimmune disease; those lacking this genetic vulnerability
may develop transient heart-reactive antibodies, but be
protected against chronic autoimmune disease.
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Clinical implications. This study has demonstrated that
heart-reactive antibodies are common in serum from patients
with myocarditis or cardiomyopathy as well as in serum
from overtly healthy individuals. Indirect immunofluores-
cence screening tests indicated that 59% of the patients with
myocarditis, 20% of the patients with cardiomyopathy and
none of the healthy volunteers had a high titer of antibodies
to heart tissue. Thus, the indirect immunofluorescence pro-
cedure could be used as an initial noninvasive test to identify
patients who have immune-mediated cardiac dysfunction.
The fluorescence data support the hypothesis that autoim-
mune processes may be involved in a relatively large sub-
group of patients with myocarditis. The presence of similar
heart autoantibodies in some patients with cardiomyopathy
with a nondiagnostic endomyocardial biopsy suggests that
these patients may have had prior undetected myocarditis or
ongoing myocarditis that is not evident from randomly
drawn endomyocardial biopsy samples. All patients in this
study had recent onset of congestive heart failure; the
prevalence and characterization of cardiac autoantibodies in
patients with long-standing idiopathic dilated cardiomyopa-
thy has yet to be addressed.
Although the Western immunostaining results demon-
strate that virtually all sera, including samples from healthy
volunteers, reacted with cardiac antigens present in a normal
heart extract, the procedure has the potential to aid in the
identification of specific relevant heart autoantigens. With
technical improvements leading to the identification of rele-
vant cardiac antigens, quantitative assays for each could be
developed. This would contribute to improved understand-
ing of the autoimmune aspects of cardiac disorders and offer
a noninvasive means of monitoring the efficacy of therapeu-
tic protocols.
Technical support was provided by Pat Jones. Paula Nawrocki, Craig Narins
and Scott Wulff.
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